PDCD1 polymorphisms are not associated with Takayasu's arteritis in Turkey

Haner Direskeneli1, Ezgi Tuna-Erdoğan, Feyza Gündüz

  • 1Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey. hanerdireskeneli@gmail.com

Insights

Genetic variations in the PDCD1 gene, specifically PD-1.3, PD-1.5, and PD-1.6 polymorphisms, were investigated for their role in Takayasu

Area of Science:

  • Immunogenetics
  • Rheumatology
  • Vascular Biology

Background:

  • Takayasu's arteritis (TA) is a rare, chronic inflammatory condition affecting large arteries, primarily the aorta and its branches.
  • The etiology of TA remains largely unknown, but associations with autoimmune diseases suggest a genetic component.
  • Programmed death-1 (PD-1) protein, encoded by the PDCD1 gene, plays a crucial role in immune regulation and has been linked to various autoimmune disorders and vasculitides.

Purpose of the Study:

  • To investigate the potential association between single nucleotide polymorphisms (SNPs) in the PDCD1 gene and susceptibility to Takayasu's arteritis (TA).
  • To analyze PD-1.3, PD-1.5, and PD-1.6 polymorphisms within the PDCD1 gene in a Turkish population with TA.

Main Methods:

  • A case-control study involving 229 TA patients meeting the 1990 ACR classification criteria and 193 healthy controls (HC).
  • Genotyping of PDCD1 gene polymorphisms (PD-1.3, PD-1.5, PD-1.6) was performed using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) analysis.

Main Results:

  • No significant difference in the distribution of the PD-1.5 TT genotype was observed between TA patients and healthy controls (13.3% vs. 11.4%).
  • PD-1.3 and PD-1.6 polymorphisms showed limited variability and did not differ between the study groups.
  • Rare genotypes, such as PD-1.3 AA (1.4% vs. 1.0%) and PD-1.6 AG (22.4% vs. 19.2%), were similarly present in both TA patients and controls.

Conclusions:

  • The studied PDCD1 gene polymorphisms (PD-1.3, PD-1.5, PD-1.6) are not associated with susceptibility to Takayasu's arteritis in the investigated Turkish population.
  • These findings suggest that variations in these specific PDCD1 gene loci do not confer a predisposition to TA, despite their known links to other autoimmune conditions.
Abstract

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...